BenevolentAI Investor Conference Presentation Deck

Our flexible business model unlocks multiple routes to value creation Al-Discovery Tools Knowledge Graph Precision Medicine 000 B 000 Target Identification Molecular Design B C U GIND OWNED PIPELINE Platform-generated assets LICENSING Platform-generated assets PLATFORM COLLABORATIONS Economic Benefits NON-COMMERCIAL COLLABORATIONS ESG In-house development Out-licensed at IND, end Phase I or end II Platform Validation Platform Validation Data generated enriches the Benevolent Platform™ Data generated enriches the Benevolent Platform™ Benevolent 17

View entire presentation